ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Association of Lipid and Blood Glucose Profiles with MASLD Among Young Adults.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fasting blood glucose to HDL-C ratio as a potential biomarker for prostate cancer risk classification.BMC urology · 2026Article
- Association of the total cholesterol-high-density lipoprotein-glucose index with metabolic-associated steatotic liver disease: a 5-year retrospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comparative analyses of metabolic biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in young adults remain limited. While previous studies have examined metabolic predictors of MASLD, few have specifically focused on young adult populations in China, where rising obesity rates and lifestyle changes are creating new patterns of metabolic risk. Methods: In this retrospective study, young adults underwent abdominal ultrasounds and metabolic profiling were included in the analysis. Eleven blood lipid and glucose profiles were analyzed. MASLD is defined according to the liver ultrasound findings and self-reported alcohol consumption. Multivariable logistic regression and ROC curves were employed to analyze the association between each indicator and the outcome. Based on the five indicators most strongly indicators, the number of major risk factors for patients was defined, and a logistic regression model with adjusted covariates was used to investigate the impact of the coexistence of risk factors on MASLD. Results: A total of 24.55% (n=10,332) of participants aged 35 years and under had MASLD. All indicators were significantly associated with MASLD separately after adjusting for covariates. Elevated TG/HDL-C ratio≥ 1.44 (OR: 3.87, 95% CI:3.62, 4.15), TyG ≥ 8.8 (OR: 3.78, 95% CI: 3.51, 4.07), and TG≥ 1.61mmol/L (OR: 3.62, 95% CI: 3.38, 3.88) exhibited the strongest associations with MASLD. ROC analysis indicated comparable predictive performance for TG/HDL ratio (AUC: 0.85, 95% CI:0.84, 0.85) and TyG (AUC: 0.83, 95% CI:0.83, 0.84). Cumulative risk factor analysis indicated that individuals with more risk factors suffered increasing risk compared to those with no risk factors. The associations were stable among participants with different amount of metabolic risk factors. Conclusion: Our study establishes that lipid ratios and insulin resistance indices maintain strong predictive value for MASLD in young Chinese adults, even when traditional metabolic risk factors are absent. These findings highlight the importance of incorporating TG/HDL-C ratio and TyG index into routine health screenings for early MASLD detection in young populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.